Share on StockTwits

GlaxoSmithKline plc (LON:GSK) has received a consensus recommendation of “Hold” from the twenty-three brokerages that are covering the company, Stock Ratings Network.com reports. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is GBX 1,712.61 ($28.81).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1623.00 on Friday. GlaxoSmithKline plc has a 52-week low of GBX 1200.668 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1607. and its 200-day moving average is GBX 1619.. The company’s market cap is £78.131 billion.

The company also recently announced a dividend, which is scheduled for Thursday, July 10th. Shareholders of record on Wednesday, May 14th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.17%. The ex-dividend date is Wednesday, May 14th.

A number of analysts have recently weighed in on GSK shares. Analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday. They now have a GBX 1,660 ($27.92) price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of GlaxoSmithKline plc in a research note on Thursday. They now have a GBX 1,650 ($27.75) price target on the stock. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline plc in a research note on Wednesday. They now have a GBX 1,730 ($29.10) price target on the stock.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.